NEW YORK, July 22, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Theravance Inc. (NASDAQ: THRX), and NewLink Genetics Corporation (NASDAQ: NLNK). Free research report on Amgen can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AMGN On Tuesday, July 21, 2015, the NASDAQ Composite ended at 5,208.12, down 0.21%, the Dow Jones Industrial Average declined 1.00%, to finish the day at 17,919.29, and the S&P 500 closed at 2,119.21, down 0.43%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
On Tuesday, shares in Amgen Inc. recorded a trading volume of 2.67 million shares, lower than their three months average volume of 3.17 million shares. The stock ended the day 0.39% lower at $163.70. Shares of the company traded at a PE ratio of 22.09. Although, Amgen Inc.'s stock has lost 2.35% in the previous three months, it has advanced 1.85% in the last one month and 3.82% on YTD basis. The company is trading above its 50-day and 200-day moving averages by 3.38% and 4.37%, respectively. Furthermore, shares of Amgen Inc. have a Relative Strength Index (RSI) of 60.91. Sign up and read the free notes on AMGN at:
Exelixis Inc.'s stock gained 2.89%, to close Tuesday's session at $6.05. The stock recorded a trading volume of 22.10 million shares, much above its three months average volume of 4.31 million shares. Over the last one month and the previous three months, Exelixis Inc.'s shares have surged 57.55% and 97.07%, respectively. Additionally, the stock has rallied 320.14% since the start of this year. The company is trading 70.31% and 144.98% above its 50-day and 200-day moving averages, respectively. Furthermore, Exelixis Inc.'s stock has an RSI of 84.04. The complimentary notes on EXEL can be downloaded in PDF format at:
XOMA Corp.'s stock finished Tuesday's session 2.77% lower at $4.39. A total of 3.69 million shares were traded, which was above its three months average volume of 3.21 million shares. Over the last one month and the previous three months, XOMA Corp.'s shares have surged 13.27% and 19.75%, respectively. Additionally, the stock has gained 22.42% since the beginning of 2015. The company's shares are trading above their 50-day and 200-day moving averages by 15.63% and 13.27%, respectively. XOMA Corp.'s stock has an RSI of 57.02. Register for free on Equity Research Institute and access the latest research on XOMA at:
On Tuesday, shares in Theravance Inc. ended the session 0.62% lower at $15.92. The stock reported a trading volume of 0.32 million shares, below its three months average volume of 0.60 million shares. Theravance Inc.'s shares have lost 15.25% in the last one month and 4.27% in the previous three months. However, the stock has gained 12.51% on YTD basis. The stock is trading 0.61% above its 200-day moving average. Moreover, shares of Theravance Inc. have an RSI of 39.56. The complete research on THRX is available for free at:
NewLink Genetics Corp.'s stock edged 0.73% lower, to close the day at $54.24. The stock recorded a trading volume of 0.38 million shares, below its three months average volume of 0.60 million shares. Over the last one month and over the past three months, NewLink Genetics Corp.'s shares have gained 21.21% and 1.97%, respectively. Furthermore, the stock has advanced 36.45% since the start of this year. The company's shares are trading 20.32% above their 50-day moving average and 30.31% above their 200-day moving average. Additionally, NewLink Genetics Corp. traded at a PE ratio of 18.45 and has an RSI of 73.25. Free in-depth research on NLNK is available at:
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ERI has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com.
ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.